• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Peterson Health Releases Framework for Digital Assessments


The assessment framework developed by Peterson Health Technology Institute and the Institute for Clinical and Economic Research will prioritize products’ clinical benefits and economic impact of digital health technologies. The companies will announce the first set of health technologies to be reviewed by mid-October.

Peterson Health Technology Institute (PHTI) has released its framework to assess whether technology solutions improve health and lower costs. The framework was developed in partnership with the Institute for Clinical and Economic Research (ICER).

The assessments will evaluate digital therapeutics, chronic care management apps, remote patient monitoring, and administrative technologies, many of which include artificial intelligence. The assessment framework will prioritize products’ clinical benefits and economic impact, as well as their effects on health equity, privacy, and security.

Caroline Pearson

Caroline Pearson

“The digital health market is flooded with an overwhelming number of new technologies claiming to transform healthcare delivery in all sorts of ways,” Caroline Pearson, executive director of the Peterson Center on Healthcare (PCH), said in a press release.

Peterson Health Technology Institute was formed in July 2023. It was launched by The Peterson Center on Healthcare with a commitment of $50 million to develop evidence-based assessments that will analyze the clinical benefits and economic impact of digital health solutions. The Peterson Center on Healthcare is a nonprofit organization founded in 2008 to develop strategies to improve quality and lower costs of healthcare. The PCH collaborates with universities, foundations, policy centers and other stakeholders, such as KFF and Civica Rx.

The development of the ICER-PHTI Assessment Framework involved experts in health technology assessment, clinical care delivery and health economics, as well as patients. The assessments are designed to help payers and providers make decisions based on clinical and economic benefits.

The selection of technologies to be evaluated will be based on market relevance, disease burden, level of spend and claimed savings, and evidence quality and availability. Similar to the ICER reviews, companies with products selected for evaluation will be given the opportunity to share evidence and information. PHTI will provide summary ratings that include whether evidence supports adoption or whether additional testing is needed.

PHTI officials said they will announce the first set of health technologies to be reviewed by mid-October.

Over the last few years, regulators have begun to grapple with how to regulate new digital technologies. In September 2020, the FDA announced the launch of the Digital Health Center of Excellence (DHCoE) within the Center for Devices and Radiological Health. This arm of the agency establishes policies and regulatory approaches for digital health technology, including mobile health devices, software as a medical device, wearables when used as a medical device, and technologies used to study medical products.

But PHTI executives say there is still no clear evidence standards and this can lead to misalignment between evidence generated by developers and what is needed by payers.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.